Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients
Publisher
Massachusetts Medical SocietyDate
2011Citation
10.1056/NEJMoa1110899
New England Journal of Medicine 365.23 (2011): 2167-2177
ISSN
0028-4793 (print); 1533-4406 (online)DOI
10.1056/NEJMoa1110899Funded by
Supported by Bristol-Myers Squibb and PfizerSubjects
Anticoagulants; Enoxaparin; Kaplan-Meier Estimate; Respiratory Insufficiency; Pyrazoles; MedicinaRights
© 2011 Massachusetts Medical SocietyAbstract
The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin. METHODS: In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2.5 mg twice daily for 30 days, or enoxaparin, administered subcutaneously at a dose of 40 mg once daily for 6 to 14 days. The primary efficacy outcome was the 30-day composite of death related to venous thromboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of systematic bilateral compression ultrasonography on day 30. The primary safety outcome was bleeding. All efficacy and safety outcomes were independently adjudicated. RESULTS: A total of 6528 subjects underwent randomization, 4495 of whom could be evaluated for the primary efficacy outcome - 2211 in the apixaban group and 2284 in the enoxaparin group. Among the patients who could be evaluated, 2.71% in the apixaban group (60 patients) and 3.06% in the enoxaparin group (70 patients) met the criteria for the primary efficacy outcome (relative risk with apixaban, 0.87; 95% confidence interval [CI], 0.62 to 1.23; P = 0.44). By day 30, major bleeding had occurred in 0.47% of the patients in the apixaban group (15 of 3184 patients) and in 0.19% of the patients in the enoxaparin group (6 of 3217 patients) (relative risk, 2.58; 95% CI, 1.02 to 7.24; P = 0.04). CONCLUSIONS: In medically ill patients, an extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin. Apixaban was associated with significantly more major bleeding events than was enoxaparin
Files in this item
Google Scholar:Goldhaber, Samuel Z.
-
Leizorovicz, Alain
-
Kakkar, Ajay K.
-
Haas, Sylvia K.
-
Merli, Geno
-
Knabb, Robert M.
-
Weitz, Jeffrey I.
-
ADOPT Trial Investigators
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Socioeconomic constraints, environmental impacts and drivers of change in the Congo Basin as perceived by loggins companies
Ruiz Pérez, Manuel; Driss, Ezzine de Blas; Nasi, Robert; Sayer, Jeffrey A.; Karsenty, Alain; Sassen, Marieke; Angoué, Claudine; Gami, Norbert; Ndoye, Ousseynou; Ngono, Grégoire; Nguinguiri, Jean-Claude; Nzala, Donatien; Toirambe, Benjamin; Yalibanda, Yves
2006 -
Medical versus surgical approach to initial treatment in septic arthritis: A single spanish center’s 8-year experience
Flores-Robles, Bryan Josué; Jiménez Palop, Mercedes; Sanabria Sanchinel, Abel alejandro; Andrus, Robert Francis; Royuela Vicente, Ana; Sanz Pérez, Marta Isabel; Espinosa Malpartida, María; Ramos Giráldez, Consuelo; Merino Argumanez, Carolina; Villa Alcázar, Fernando; Andreu Sánchez, José Luis; Godoy Tundidor, Hildegarda; Campos Esteban, José; Sanz Sanz, Jesús; Barbadillo Mateos, Carmen; Isasi Zaragoza, Carlos; Mulero Mendoza, Juan
2019-01 -
Effectiveness of a cognitive behavioral intervention in patients with medically unexplained symptoms: Cluster randomized trial
Lápez-García-Franco, Alberto; Del-Cura-González, Ma Isabel; Caballero Martínez, Luis; Sanz-Cuesta, Teresa; Díaz-García, Marta Isabel; Rodríguez Monje, Ma Teresa; Chahua, Marcela; Mũoz-Sanchez, Inmaculada; Serrano-González, Dolores; Rollán-Llanderas, Teresa; Nieto-Blanco, Esther; Losada-Cucco, Liliana; Caballero-Martínez, Fernando; Sanz-García, Nuria; Pose-García, Belén; Jurado-Sueiro, Montserrat; Rey, ManuelaLuque; De Blas González, Francisca García; Abanto, Ma Angeles Miguel; Bayona, Teresa Sanz; Ayllán-Camargo, Rafaela; Lopez, Inmaculada Santamaría; Hernando, María Luisa Santiago; Beltran-Alvarez, Rosario; Aguilar-Gutierrez, Ana Isabel; Mota-Rodriguez, Jose Luis; Cosculluela-Pueyo, Rafaél; Lápez-Martín-Aragán, Teresa; Bonilla-Sanchez, Rosa; Aritieda-González-Granda, Ma Carmen; Razola-Rincán, Raquel; Sanchez-de-la-Ventana, Ma Angeles; Martinez-Guinea, Concepcián; Huerta-Galindo, Luis; Barrio-Ovalle, Ana Belén; Miguel-Martín, Susana; Portero-Fraile, Paz; Pensado-Freire, Higinio; Herrera-Garcia, María Luisa; Azcoaga-Lorenzo, Amaya; Gámez-García, Inés; Llamas-Sandino, Nuria; Lápez-Borja, Isabel; Maldonado-Castro, Hortensia; Lumbreras-Villarán, Patricia; Ascanio-Durán, Carlos
2012-12-12